Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
Running, not enrolling · Phase 1 · Has a placebo group
Conditions studied: Cystic Fibrosis
In brief
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Key facts
- Study ID
- NCT06154447
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 165
- Starts
- 2023-12-12
- Expected to finish
- 2026-07-16
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Joe DiMaggio Cycstic Fibrosis & Pulmonary Center — Hollywood, Florida, United States
- AdventHealth Medical Group Pulmonology at Orlando Ridgewood — Orlando, Florida, United States
- Altasciences Clinical Kansas — Overland Park, Kansas, United States
- Kentucky Children's Hospital — Lexington, Kentucky, United States
- Boston Children's Hospital — Boston, Massachusetts, United States
- University of Minnesota -Pulmonology — Minneapolis, Minnesota, United States
- Billings Clinic, Pediatric Pulmonary Dept. — Billings, Montana, United States
- New York Medical College — Hawthorne, New York, United States
- ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC — Toledo, Ohio, United States
- Cook Children's Pulmonology — Fort Worth, Texas, United States
- University of Utah Hospital - Pulmonology — Salt Lake City, Utah, United States
- Vermont Lung Center — Colchester, Vermont, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.